Skip to main content

Table 1 Participants characteristics

From: Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study

Participants

114

Experience in Treatment of PDAC

 < 5 years

13 (11.4%)

 5–10 years

29 (25.4%)

 > 10 years

72 (63.2%)

Scope of practice

 Surgery

99 (86.8%)

  General surgery

84 (73.7%)

  HPB surgery

15 (13.2%)

 Oncology

15 (13.2%)

  Medical oncology

12 (10.5%)

  Radiation oncology

2 (1.8%)

  Gastroenterology

1 (0.9%)

Origin of participants

 Europe

99 (86.8%)

 Africa

8 (7%)

 Middle East

5 (4.4%)

 South America

2 (1.8%)

 Countries

37